IT201900025069A1 - ORAL COMPOSITION TO PROMOTE THE REGENERATION OF PERIPHERAL NERVES - Google Patents

ORAL COMPOSITION TO PROMOTE THE REGENERATION OF PERIPHERAL NERVES

Info

Publication number
IT201900025069A1
IT201900025069A1 IT102019000025069A IT201900025069A IT201900025069A1 IT 201900025069 A1 IT201900025069 A1 IT 201900025069A1 IT 102019000025069 A IT102019000025069 A IT 102019000025069A IT 201900025069 A IT201900025069 A IT 201900025069A IT 201900025069 A1 IT201900025069 A1 IT 201900025069A1
Authority
IT
Italy
Prior art keywords
regeneration
promote
oral composition
peripheral nerves
nerves
Prior art date
Application number
IT102019000025069A
Other languages
Italian (it)
Inventor
Daniele Pietra
Alice Borghini
Original Assignee
Alidans S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alidans S R L filed Critical Alidans S R L
Priority to IT102019000025069A priority Critical patent/IT201900025069A1/en
Publication of IT201900025069A1 publication Critical patent/IT201900025069A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
IT102019000025069A 2019-12-20 2019-12-20 ORAL COMPOSITION TO PROMOTE THE REGENERATION OF PERIPHERAL NERVES IT201900025069A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IT102019000025069A IT201900025069A1 (en) 2019-12-20 2019-12-20 ORAL COMPOSITION TO PROMOTE THE REGENERATION OF PERIPHERAL NERVES

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT102019000025069A IT201900025069A1 (en) 2019-12-20 2019-12-20 ORAL COMPOSITION TO PROMOTE THE REGENERATION OF PERIPHERAL NERVES

Publications (1)

Publication Number Publication Date
IT201900025069A1 true IT201900025069A1 (en) 2021-06-20

Family

ID=70295621

Family Applications (1)

Application Number Title Priority Date Filing Date
IT102019000025069A IT201900025069A1 (en) 2019-12-20 2019-12-20 ORAL COMPOSITION TO PROMOTE THE REGENERATION OF PERIPHERAL NERVES

Country Status (1)

Country Link
IT (1) IT201900025069A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202200008894A1 (en) * 2022-05-03 2023-11-03 Biodue S P A Nutraceutical composition including citicoline, vitamin D3 and hemp oil.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014049566A2 (en) * 2012-09-28 2014-04-03 Stellenbosch University Nutritional kit
US10478414B2 (en) * 2017-04-04 2019-11-19 Alicia Marie Wiggins Neuroregeneration supplement

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014049566A2 (en) * 2012-09-28 2014-04-03 Stellenbosch University Nutritional kit
US10478414B2 (en) * 2017-04-04 2019-11-19 Alicia Marie Wiggins Neuroregeneration supplement

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
AINSWORTH EAGILLESPIE KM: "Estimation of total phenol content and other oxidation substrate in plant tissues using Folin-Ciocalteu reagent", NATURE PROTOCOLS, vol. 2, 2007, pages 875 - 875
AZIZ N ET AL: "Supplementation of Cannabis sativa L. Leaf powder accelerates functional recovery and ameliorates haemoglobin level following an induced injury to sciatic nerve in mouse model", PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES 2019 PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES PAK, vol. 32, no. 2, 31 March 2019 (2019-03-31), pages 785 - 792, XP009522236, ISSN: 1011-601X *
CHEMICAL ABSTRACTS, Columbus, Ohio, US; abstract no. 1077-28-7
GUNDOGDU ELIF BASARAN ET AL: "CDP-choline modulates matrix metalloproteinases in rat sciatic injury", JOURNAL OF SURGICAL RESEARCH, ACADEMIC PRESS INC., SAN DIEGO, CA, US, vol. 200, no. 2, 8 October 2015 (2015-10-08), pages 655 - 663, XP029352465, ISSN: 0022-4804, DOI: 10.1016/J.JSS.2015.10.003 *
HASEGAWA K ET AL: "Effects of a vitamin B complex on functional recovery after nerve injury", FOLIA PHARMACOLOGICA JAPONICA 1978 JP, vol. 74, no. 6, 1978, pages 721 - 734, XP009522237, ISSN: 0015-5691 *
HORASANLI BAHRIYE ET AL: "Comparative evaluation of the electrophysiological, functional and ultrastructural effects of alpha lipoic acid and cyanocobalamin administration in a rat model of sciatic nerve injury.", JOURNAL OF BACK AND MUSCULOSKELETAL REHABILITATION 22 SEP 2017, vol. 30, no. 5, 22 September 2017 (2017-09-22), pages 967 - 974, XP009522238, ISSN: 1878-6324 *
MARION MONTAVA ET AL: "Vitamin D3 potentiates myelination and recovery after facial nerve injury", EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY : OFFICIAL JOURNAL OF THE EUROPEAN FEDERATION OF OTO-RHINO-LARYNGOLOGICAL SOCIETIES (EUFOS) : AFFILIATED WITH THE GERMAN SOCIETY FOR OTO-RHINO-LARYNGOLOGY - HEAD AND NECK SURGERY, vol. 272, no. 10, 27 September 2014 (2014-09-27), DE, pages 2815 - 2823, XP055722742, ISSN: 0937-4477, DOI: 10.1007/s00405-014-3305-y *
MCKAY HART ANDREW ET AL: "Pharmacological enhancement of peripheral nerve regeneration in the rat by systemic acetyl-L-carnitine treatment", NEUROSCIENCE LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 334, no. 3, 15 November 2002 (2002-11-15), pages 181 - 185, XP085019218, ISSN: 0304-3940, DOI: 10.1016/S0304-3940(02)00982-5 *
RAFAELA V. SILVA ET AL: "Long-Chain Omega-3 Fatty Acids Supplementation Accelerates Nerve Regeneration and Prevents Neuropathic Pain Behavior in Mice", FRONTIERS IN PHARMACOLOGY, vol. 8, 17 October 2017 (2017-10-17), CH, XP055722740, ISSN: 1663-9812, DOI: 10.3389/fphar.2017.00723 *
REMINGTON: "the Science and practice of Pharmacy", 2012

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202200008894A1 (en) * 2022-05-03 2023-11-03 Biodue S P A Nutraceutical composition including citicoline, vitamin D3 and hemp oil.

Similar Documents

Publication Publication Date Title
NZ742819A (en) Inhibitors of cxcr2
UY36056A (en) "FUSIONED BICYCLIC HETEROARILO OR ARILO COMPOUNDS".
EA201692301A1 (en) DERIVATIVES OF BORONIC ACID AND THEIR THERAPEUTIC APPLICATION
EA201790273A1 (en) FLAGELLIN COMPOSITIONS AND THEIR APPLICATION
CL2015002635A1 (en) Compounds and compositions for the treatment of parasitic diseases
PE20180024A1 (en) TRIAZOLOPYRAZINONES AS PDE1 INHIBITORS
ECSP13012573A (en) 6-amino-nicotinamides substituted as modulators of KCNQ2 / 3
EA201790599A1 (en) COMPOUNDS AND COMPOSITIONS AS KINAZ INHIBITORS
EA201890771A1 (en) SALT AND SOLID FORMS OF MONOBACTAN ANTIBIOTICS
IT201600121601A1 (en) ORAL COMPOSITION FOR THE TREATMENT OF GASTROESOFAGEO REFLUX AND LARINGO-FARINGEO REFLUX
EA201791696A1 (en) COMPOSITION FOR THE TREATMENT OF VENO-ACCLUSION DISEASE OF THE LIVER
CL2014001861A1 (en) Compounds derived from benzyl sulfonamide, mogat-2 inhibitors; crystalline compound; pharmaceutical composition; and its use in the treatment of hypertriglyceridemia.
FR3022462B1 (en) ORAL COMPOSITION OF ANTI-TNFALPHA ANTIBODY
ECSP13012453A (en) 2-oxy-quinoline-3-carboxamides substituted as KCNQ2 / 3 modulators
EA201591259A1 (en) SOLID FORMS OF HINAZOLIN DERIVATIVE AND THEIR APPLICATION AS A BRAF INHIBITOR
IL292085A (en) Oral care composition
SI3124048T1 (en) Composition for oral use in the treatment of gastro-oesophageal reflux disease or discomfort
IT201900025069A1 (en) ORAL COMPOSITION TO PROMOTE THE REGENERATION OF PERIPHERAL NERVES
EA201991373A1 (en) ROR GAMMA MODULATORS (RORγ)
CL2020000187S1 (en) Toothbrush.
MA51009A (en) ORAL CARE COMPOSITION
FR3025096B1 (en) GEL / GEL COMPOSITION CONTAINING ANTI-TRANSPARENT ACTIVE INGREDIENT
IL271658A (en) New oral formulations of belinostat
DE202019104765U8 (en) Dental brush
EA201690236A1 (en) INDOL-3-CARBINOLA DERIVATIVES